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p63, a homologue of the p53 gene, is considered to be essential for the normal development of stratified epithelia including
urothelium. To examine possible roles of p63 in urothelial tumorigenesis, p63 expression was systematically examined in normal
urothelium, low-grade papillary noninvasive (LPN) urothelial tumours, and high-grade or invasive carcinomas, using either an isoform-
nonspecific or a DN-isoform-specific antibody. Expression profiles of p63 were also analysed in cultured cells. Immunoreactivity with
the two antibodies was virtually identical in tissue samples examined. Basal and intermediate cell layers of normal urothelium showed
intense nuclear p63 immunostaining. This normal staining pattern was preserved in a majority of LPN tumours, whereas it was
frequently impaired in high-grade or muscle-invasive carcinomas. At the mRNA level, DNp63 expression predominated over TAp63,
and amounts of DNp63 mRNA correlated with p63 immunoreactivity, confirming that DNp63 accounts for p63 expressed in
urothelial tissues. In cultured cells, DNp63 was also expressed in low-grade tumour cells as well as normal urothelial cells, but
undetectable in high-grade aggressive carcinoma cells. Interestingly, impaired DNp63 expression significantly associated with reduced
b-catenin expression that was possibly related to progression of urothelial neoplasms. Thus, impaired DNp63 expression
characterises aggressive phenotypes of urothelial neoplasms.
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In clinical management, it is important to recognise two major
variants of urothelial neoplasms (Lee and Droller, 2000). The first
variant, which constitutes approximately 70% of the neoplasms,
presents as low-grade papillary lesions that usually are confined to
the mucosa. This variant is often multifocal and recurs, but has
limited potential to progress to muscle-invasive stage (Grossman,
1996; Lee and Droller, 2000). The 5-year survival rate of this
variant can reach 90% if treated appropriately. The second variant,
which accounts for 30% of urothelial neoplasms, presents as high-
grade invasive disease at diagnosis and has a high risk to develop
incurable distant metastases (Steinberg et al, 1992). Extensive
clinicopathologic studies suggest that the majority of invasive
carcinomas do not originate in papillary noninvasive lesion
(Brawn, 1982), but in flat carcinoma in situ (CIS) or can arise de
novo (Schalken et al, 1992; Hudson and Herr, 1995). Accumulating
molecular analyses indicate that urothelial neoplasm develops via
two distinctive carcinogenesis pathways (Cairns et al, 1991; Spruck
et al, 1994; Orlow et al, 1995; Lee and Droller, 2000). Low-grade
papillary noninvasive (LPN) tumours are frequently associated
with deletions of chromosome 9 and defects of p16, a cyclin-
dependent kinase inhibitor, but not with mutations of p53 tumour
suppressor gene (Spruck et al, 1994; Orlow et al, 1995). In contrast,
invasive urothelial carcinomas and CIS are primarily associated
with dysfunction of p53 and pRb (Cairns et al, 1991; Spruck et al,
1994). Thus, urothelial neoplasms appear to develop and progress
via at least two distinct pathways with different biological
behaviour and clinical outcome; the papillary noninvasive and
CIS/invasive pathways.
p63 is a homologue of the p53 tumour suppressor gene located
at 3q27–3q29 and is also known as p51, p40, p73L,o rKET
(Schmale and Bamberger, 1997; Osada et al, 1998; Senoo et al,
1998; Trink et al, 1998; Yang et al, 1998). This gene encodes for two
major classes of protein: those containing an acidic amino
terminus analogous to the transactivating domain of p53
(TAp63), and those with a truncated amino terminus that lacks
this region (DNp63). In addition, alternative splicing at the
carboxyl terminus yields at least three p63 isoforms (a, b, and g)
(Osada et al, 1998; Yang et al, 1998). TAp63 isoforms can
transactivate p53 target genes such as p21, and induce apoptosis
when overproduced (Osada et al, 1998; Yang et al, 1998), whereas
DNp63 isoforms potentially suppress transactivation by both p53
and TAp63 isoforms in a dominant-negative manner (Yang et al,
1998).
Although the function of the p63 is not fully understood, the
striking epithelial defects throughout the body seen in p63
knockout mice (Mills et al, 1999; Yang et al, 1999) suggest that
this gene plays a key role in maintaining basal, progenitor cell
populations of the stratified epithelia (Yang et al, 1999; Yang and
McKeon, 2000). In fact, p63 is selectively expressed in the basal cell
or progenitor cell compartment of stratified epithelia including
urothelium in human tissues (Yang et al, 1998, 1999; Di Como et al,
2002). Moreover, genitourinary abnormalities have been docu-
mented in patients with the ectrodactyly, ectodermal dysplasia,
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yand cleft palate syndrome caused by heterozygous germline
mutations of p63 (Rollnick and Hoo, 1988; Celli et al, 1999).
Based on these findings, p63 may play critical roles in the normal
development and maintenance of the human urothelium.
Despite the initial enthusiasm surrounding the cloning of p63 as
a homologue of p53 tumour suppressor gene, mutational analyses
have demonstrated rare p63 mutations (o4%) in a large number
of human primary tumours including urothelial tumours (Osada
et al, 1998; Hagiwara et al, 1999; Sunahara et al, 1999; Park et al,
2000). Therefore, p63 is unlikely to be a tumour suppressor gene
that conforms to the two-hit model of carcinogenesis. On the other
hand, DNp63 is considered to have oncogenic properties based on
the following observations: (1) DNp63 overexpression is often
observed (Parsa et al, 1999; Hibi et al, 2000) and it enhances
oncogenic growth in squamous cell carcinomas (Hibi et al, 2000);
(2) DNp63 could function as dominant negatives against the p53
tumour suppressor activities (Yang et al, 1998); and (3) DNp63
overexpression induces nuclear accumulation of b-catenin and
activates the b-catenin signalling that promotes cell proliferation
(Patturajan et al, 2002).
The current study was designed to assess the possible roles of
altered p63 expression in the development of urothelial neoplasms.
We systematically analysed p63 expression profiles in normal
urothelium and urothelial neoplasms of various pathologic
phenotypes using tissue samples and cultured cells. This study
demonstrates that LPN tumours highly preserve the normal p63
expression pattern characterised by abundant and well-organised
DNp63 expression, while high-grade/invasive urothelial carcino-
mas frequently show a decrease or loss of DNp63 expression.
Furthermore, diminished DNp63 expression associates with
reduced expression of b-catenin that plays important roles in cell
adhesion and signal transduction (Conacci-Sorrell et al, 2002).
MATERIALS AND METHODS
Tissue samples
Seventy-two urothelial tumour specimens (obtained from 61
patients) and five normal urothelium specimens (from five
patients with renal cell carcinoma) were used for immunohisto-
chemistry. For the analysis of mRNA, three normal and 32
neoplastic urothelial tissues corresponding to those for immuno-
histochemistry were snap-frozen in ISOGEN (Wako Co., Osaka,
Japan) immediately after the surgical removal and stored at  801C.
Histologic grade of the tumour was determined according to the
1973 World Health Organization grading system (Mostofi, 1973)
by two pathologists (JK and TT), without information on p63
expression status. Tumours composed of grades 1–2 cells were
classified as low-grade, while those containing grade 3 cells as
high-grade. The stage of the tumour was determined based on the
1997 TNM system (Sobin and Wittekind, 1997). Informed consent
was obtained from each patient before commencing experiments.
Human cell lines
To analyse p63 expression in normal human urinary tract in vitro,
normal human urothelial (NHU) cells and normal human ureteral
stromal cells were cultivated as reported elsewhere (Kawakami
et al, 2002). Also examined were four established human bladder
cancer cell lines: RT-4, JTC30, EJ, and T24. RT-4 was derived from
papilloma of the urinary bladder (Rigby and Franks, 1970). JTC30
is a cell line established in our laboratory from a patient with well-
differentiated papillary bladder tumour (Kakuya et al, 1983). EJ
was established from invasive, poorly differentiated urothelial
carcinoma of the bladder (Evans et al, 1977; Hastings and Franks,
1983). T24 was derived from a primary lesion of grade 3 carcinoma
of the bladder (Bubenik et al, 1973).
Immunohistochemistry
Immunostaining was performed in paraffin-embedded tissue
specimens using a mouse anti-human p63 monoclonal antibody,
4A4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), which
recognises all six p63 isoforms (Yang et al, 1998, 1999). Five-
micrometre sections were deparaffinised, rehydrated, and treated
in 0.3% hydrogen peroxide in methanol for 30min to exhaust
endogenous peroxidase activity. The sections were pretreated in a
550W microwave oven three times for 5min in 10mM citrate
buffer (pH 6.0). After blocking of nonspecific binding with 10%
goat serum, sections were incubated with the 4A4 antibody at a
1:200 dilution for 1h at room temperature. After washing with
phosphate-buffered saline, the sections were incubated with a
horseradish peroxidase-labelled secondary antibody (HISTOFINE
Simple Stain MAX PO(M), Nichirei, Tokyo, Japan) for 30min at
room temperature. Peroxidase activity was localised using 3,3-
diaminobenzidine (Nichirei, Tokyo, Japan). Standardised devel-
opment time periods allowed accurate comparison of all samples.
Finally, the sections were counterstained slightly with haematox-
ylin, dehydrated, and mounted. In negative controls, the primary
antibody was substituted for nonimmune mouse sera. Nonneo-
plastic prostate glands were used as positive controls (Signoretti
et al, 2000). The slides were independently reviewed by two of the
authors (KF and KS) who were blinded to the clinicopathologic
data. Immunoreactivity was evaluated for staining intensity (none,
weak, intense) and extent (none, o10%; heterogeneous, 10–50%;
homogeneous, X50%) of each tumour. Immunostaining using a
rabbit anti-p40 polyclonal antibody Ab-1 (Oncogene Research
Products, Boston, MA, USA; at 1:2000 dilution) was also
performed to specifically detect DNp63 (Hibi et al, 2000). Unless
stated otherwise, the 4A4 antibody was used in all protein study.
p53 and b-catenin expression was examined using mouse
monoclonal antibodies, PAb1801 (Oncogene Science, Cambridge,
MA, USA; at 1:50 dilution) and clone 14 (Transduction
Laboratories, Lexington, KY, USA; at 1:250 dilution), respectively.
Nuclear p53 staining in at least X10% of tumour cells was
considered positive, as described previously (Koga et al, 2000).
This criterion was based on the report in which the p53 gene
mutations strongly correlated with positive nuclear staining in
X10% of tumour cells when the PAb1801 was used (Esrig et al,
1993). For b-catenin expression, the staining pattern similar to that
in the normal urothelium (homogeneously positive staining at the
cell membrane) was evaluated as normal. Negative and hetero-
geneously positive staining of the cell membrane was described as
reduced. Nuclear immunoreactivity was also evaluated separately
from membranous immunoreactivity.
Reverse transcription–polymerase chain reaction
(RT–PCR)
Total RNA extraction from tissue homogenates or cell lysates, and
first-strand cDNA synthesis was performed as previously reported
(Kawakami et al, 2001b). Levels of TAp63 and DNp63 mRNAs were
estimated by semiquantitative RT–PCR-based assay with hypox-
anthine phosphoribosyltransferase 1 (HGPRT) served as an
internal control as previously described (Kawakami et al, 2001b).
Oligonucleotide primers (Table 1) were designed based upon the
reported human TAp63 and DNp63 cDNA sequences (GenBank
Accession numbers AF 075430 and AF 075431, respectively) to
span an intron to control for amplification of genomic DNA
carryover as described elsewhere (Kawakami et al, 2001a). No
detectable amplification from genomic DNA was observed with
these primers. cDNA fragments corresponding to TAp63 and
DNp63 mRNAs were amplified by PCR using primer pairs
consisting of a shared common downstream primer (R426) and
distinct upstream primers unique for each first exon but with
similar melting temperature. These primers were also designed to
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TAp63 and DNp63 transcript levels with a reasonable accuracy.
Optimum PCR conditions to amplify the HGPRT, TAp63, and
DNp63 cDNAs with specific primers were: 941C for 5min for initial
denaturation, followed by 30 cycles of 941C for 30s, 601C for 30s,
and 721C for 60s. Preliminary assays were performed to optimise
the number of PCR cycles so that those products were within the
exponential phase of amplification. PCR products were visualised
and quantified as described previously (Kawakami et al, 2001b).
Immunoblot analysis
Whole cell lysates were prepared in lysis buffer and separated in
12% sodium dodecyl sulphate–polyacrylamide gel electrophoresis
followed by transfer to polyvinylidene difluoride membranes
(Immobilon; Millipore, Bedford, MA, USA) as described previously
(Kawakami et al, 2001b). The membranes were blocked overnight
with 5% nonfat dried milk and incubated with the 4A4 antibody
for 1h at room temperature. Immunoreactive bands were
visualised as reported elsewhere (Kawakami et al, 2002).
Statistical analysis
The Fisher’s exact test or w
2 test was used to assess the significance
of proportions. The Spearman’s rank correlation test for analysis
of nonparametric data was used to test the correlation between
variables. Differences were considered significant when the P-value
was o0.05.
RESULTS
Expression of p63 protein in tissue samples
We initially evaluated p63 protein expression on normal
urothelium and urothelial tumour tissues. Immunoreactivity for
p63 was localised to nuclei of normal and neoplastic urothelial
cells. Except the urothelium, normal tissues of the kidney, ureter,
and urinary bladder were negative for p63. In normal urothelium,
almost entire basal and intermediate cells (4–5 layers from the
basement membrane) showed intense staining, but immunoreac-
tivity was undetectable in umbrella cells (Figure 1A).
Immunoreactivity of p63 according to pathologic phenotypes of
urothelial tumours is summarised in Figure 2. All the LPN tumours
were positive for p63. Twelve of 15 LPN tumours showed intense
p63 staining (Figures 1B and 2). In nine of them, immunoreactivity
was strong in basal to middle cell layers as observed in normal
urothelia; a gradual diminution of immunoreactivity towards the
superficial cell layers was observed (Figure 1C). In contrast, p63
immunoreactivity was weak (Figure 1D) or none (Figure 1E) in
most of muscle-invasive (XT2) carcinoma tissues. Metastatic
lymph nodes demonstrated p63 immunoreactivity identical to that
of their primary lesions (weak in three samples and none in two).
Six CIS associated with muscle-invasive carcinomas also showed
identical immunoreactivity to their primary lesions (intense in
one, weak in four and none in one; Figure 1F). Immunoreactivity
of p63 in CIS was also similar to that in muscle-invasive
carcinomas (Figure 2).
In stroma-invasive (T1) tumours, p63 immunoreactivity was
heterogeneous and dependent on histologic grade of the tumour;
low-grade tumours showed a slightly lower incidence of intense
staining than LPN tumours, whereas a majority of high-grade
carcinomas showed weak or undetectable immunoreactivity,
similar to muscle-invasive carcinomas (Figure 2). Intense p63
staining was observed in significantly smaller number of primary
tumour samples in high-grade (8 out of 41) or muscle-invasive
carcinomas (3 out of 23) than in low-grade (15 out of 20,
Po0.0001) or Ta–T1 tumours (18 out of 32, Po0.01), respectively.
We also performed immunostaining using the DNp63-specific
antibody Ab-1 on samples with positive p63. The staining patterns
with the Ab-1 were almost indistinguishable from those with the
4A4 in all samples examined (Figure 1G, H).
Predominant expression of DNp63 mRNA in tissue
samples
Next, we examined p63 mRNA expression profiles in normal and
tumour tissues, using DNp63- and TAp63-specific primer sets by
RT–PCR. Samples included three normal urothelial tissues, 31
primary tumours (10 LPN, four low-grade papillary T1, three high-
grade papillary Ta, seven high-grade T1, and 7 muscle-invasive)
and one metastatic lesion to the supraclavicular lymph nodes.
Photographs of gels of the representative samples are shown in
Figure 3A.
In normal urothelial tissues, DNp63 mRNA was abundantly
expressed while TAp63 mRNA was undetectable (Figure 3A).
Tumour samples also expressed DNp63 mRNA at various levels
whereas TAp63 mRNA was undetectable (Figure 3A). PCR
amplification at 36 cycles for TAp63 allowed detection of faint
bands in approximately half of tumour samples, but the amounts
of PCR products were not associated with pathologic phenotypes
of the tumours (data not shown). Consistent with the results of
immunostaining, eight of the 10 LPN tumours expressed DNp63
mRNA, while only two of eight muscle-invasive or metastatic
carcinomas were positive for DNp63 mRNA. Median and range of
the DNp63 mRNA/HGPRT mRNA ratio was 1.40 (1.37–1.55) for
normal urothelium, 0.74 (0–1.65) for LPN tumour, 0.60 (0–1.67)
for T1 tumour, and 0.00 (0–0.95) for muscle-invasive or metastatic
carcinomas. In general, the DNp63 mRNA level was not increased
in urothelial neoplasms compared with normal urothelium,
indicating that DNp63 overexpression is not associated with
urothelial tumorigenesis. The DNp63 mRNA/HGPRT mRNA ratio
was significantly correlated with immunoreactivity (rs¼0.56,
Po0.01 by Spearman’s rank correlation test; Figure 3B). Con-
sidering that the staining patterns with the Ab-1 antibody are
virtually identical to those with the 4A4 antibody, DNp63 isoforms
account for p63 protein expressed in normal and neoplastic
urothelial tissues.
Table 1 Sequences, amplicon sizes, and exon localisations of PCR primers
Primer name Sequence Exon GenBank accession no.
TAp63 amplicon size: 296bp AF 075430
F133 GGTGCGACAAACAAGATTGAG (nt 133–153) ex3
R426 GAAGGACACGTCGAAACTGTG (nt 406–426) ex4
DNp63 amplicon size; 252bp AF 075431
F12 GGAAAACAATGCCCAGACTC (nt 12–31) ex30
R426 GAAGGACACGTCGAAACTGTG (nt 241–261) ex4
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neoplastic urothelial cells
We also examined p63 expression profiles in cultured normal and
neoplastic urothelial cells. DNp63 mRNA was abundantly ex-
pressed in NHU cells but undetectable in stromal cells (Figure 4A),
confirming that p63 expression was confined to the urothelial
compartment. For tumour cells, DNp63 mRNA was strongly
expressed in low-grade cells (RT-4 and JTC30), whereas undetect-
able in high-grade aggressive cells (EJ and T24) (Figure 4A).
Relative amounts of DNp63 mRNA to HGPRT mRNA for NHU,
RT-4, and JTC30 cells were 1.29, 1.00, and 0.76, respectively.
Expression of TAp63 mRNA was undetectable at 30 cycles of PCR
amplification and barely detectable at 40 cycles (Figure 4A).
Immunoblot analysis of cell lysates also demonstrated major
immunoreactive bands at approximately 70kDa in NHU, RT-4,
Figure 1 Representative photomicrographs of immunostaining for p63, DNp63, and b-catenin in urothelial tissues. (A–F) Immunostaining of p63 with
the 4A4 antibody that recognises all isoforms of p63: (A) intense staining in normal urothelium ( 200), (B) intense staining in an LPN tumour ( 200), (C)
gradual diminution of p63 expression towards the superficial cell layers in an LPN tumour ( 100), (D) weak staining in a high-grade muscle-invasive
carcinoma ( 200), (E) loss of staining in a high-grade muscle-invasive carcinoma ( 200), and (F) weak staining in CIS ( 200). (G and H)
Immunoreactivity with the 4A4 antibody (G) is virtually identical to that with the DNp63-specific antibody Ab-1 (H)( 100). (I and J) Immunostaining of b-
catenin: (I) normal b-catenin expression with homogeneously positive staining at the cell membrane preserved in an LPN tumour ( 200) and (J) reduced
(heterogeneously positive) b-catenin expression in a muscle-invasive carcinoma ( 200).
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According to published data, candidates of p63 isoforms
responsible for this specific band are TAp63a, TAp63b, and
DNp63a (Yang et al, 1998; Hibi et al, 2000). Owing to the
predominant mRNA expression of DN isoforms rather than TA
isoforms in normal urothelial cells and low-grade urothelial
tumour cells, our results suggest that DNp63a is the predominant
isoform in these cell lines. These results are consistent with
published data in human keratinocytes (Yang et al, 1998) and
human prostate basal cells (Signoretti et al, 2000).
Expression of p63 is not associated with p53 status
Since wild-type p53 protein mediates degradation of DNp63 in
vitro (Ratovitski et al, 2001) and actually p53 mutations strongly
relate to overexpression of DNp63 in squamous cell carcinoma
(Hibi et al, 2000), we investigated the possible association of p53
status with impaired DNp63 expression in urothelial carcinoma.
The p53 status was assessed by immunohistochemistry using the
PAb1801 antibody (Esrig et al, 1993; Koga et al, 2000). As shown in
Table 2, we could not find any relation between p63 expression and
p53 status in 38 high-grade urothelial carcinoma samples (six
primary CIS, nine high-grade T1, and 23 muscle-invasive disease).
This finding is consistent with another study on urothelial
tumours (Park et al, 2000).
Impaired p63 expression is associated with reduced
b-catenin expression
A recent in vitro study has shown that DNp63 plays a role in
regulating b-catenin levels (Patturajan et al, 2002). Therefore, we
investigated the possible association of p63 expression status and
b-catenin expression pattern. Of the 47 tumour samples examined,
29 (62%) showed homogeneously positive b-catenin staining at the
cell membrane as observed in normal urothelium (Figure 1I). The
remaining 18 (38%) showed reduced expression (Figure 1J), while
positive nuclear staining was rare (4%, two out of 47). We could
not find a statistically significant association between pathologic
phenotypes and reduced b-catenin expression (4 out of 15 LPN
tumours, two out of nine high-grade T1, and 12 out of 23 muscle-
invasive carcinomas; P¼0.15). Interestingly, impaired DNp63
expression is significantly associated with reduced b-catenin
expression (Po0.01, Table 3).
DISCUSSION
This is the first study in which p63 expression has been
systematically investigated in normal human urothelium and
urothelial tumours of various pathologic phenotypes. Our
results demonstrate distinctive p63 expression patterns according
to phenotypic variants of urothelial neoplasms. First, a majority of
LPN tumours expressed p63 in basal to middle cell
layers as observed in normal urothelium, while CIS and
high-grade/muscle-invasive carcinomas showed a frequent
Figure 2 Immunoreactivity of p63 in normal urothelium and urothelial
neoplasms of various pathologic phenotypes. All three samples of high-
grade Ta tumours showed weak staining.
Figure 3 Expression of p63 mRNA in normal and neoplastic urothelial
tissues by RT–PCR analysis using isoform-specific primer sets. (A)A
representative photograph of agarose gel electrophoresis of RT–PCR
products. Lane 1, normal urothelium; lanes 2–4, LPN tumours; lane 5, high-
grade T1 carcinoma; lanes 6–8, high-grade muscle-invasive carcinomas;
lane 9, high-grade invasive carcinoma metastatic to distant lymph nodes; M,
100-bp DNA ladder. HGPRT was used as an internal control. (B)
Correlation between DNp63 mRNA/HGPRT mRNA ratio and p63
immunoreactivity in 35 urothelial tissue samples.
aMedian and range.
bAll
samples with intense staining showed homogeneous (X50%) staining.
Figure 4 Expression of p63 in cultured cells. (A) Agarose gel
electrophoresis of RT–PCR products using isoform-specific primer sets.
aAs PCR products were undetectable at 30 cycles of PCR amplification, 40
cycles were performed for TAp63. (B) Immunoblotting for p63 protein
using the 4A4 antibody.
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account for p63 protein expressed in normal urothelium and
urothelial neoplasms. Decreased expression of DNp63 is a common
feature in high-grade invasive urothelial carcinomas, indicating
that urothelial carcinogenesis is distinct from the squamous cell
carcinoma transformation strongly associated with overexpression
of DNp63 (Parsa et al, 1999; Hibi et al, 2000). Finally, we found a
significant association of the impaired DNp63 expression with
reduced b-catenin expression that relates to a worse prognosis of
bladder cancer patients (Garcia del Muro et al, 2000; Shimazui et al,
1996).
Recently, experimental studies on transgenic mice have
provided strong evidences that different genetic defects are
responsible for the two distinctive pathways of urothelial
tumorigenesis (Zhang et al, 1999, 2001). Activation of Ha-ras
alone, which plays a central role in mitogenic signal transduction,
induces urothelial hyperplasia and papillary noninvasive tumours
but not invasive carcinomas (Zhang et al, 2001), indicating that
increased cell proliferation alone can lead to development of the
papillary noninvasive urothelial tumour. On the other hand,
inactivation of p53 and pRb by SV40 large T antigen induces CIS,
invasive carcinoma, and metastatic disease (Zhang et al, 1999).
These data imply that papillary noninvasive urothelial tumours
have hyperplastic nature and are substantially different from
aggressive carcinomas. The distinct patterns of p63 expression
between LPN tumours and invasive carcinomas in the current
study further strengthen the difference in the biological characters
of these two phenotypes of urothelial neoplasms. Evaluation of p63
may be a useful tool for identifying tumours with highly malignant
potential in their early phase.
In normal urothelia, p63 expression was strong in basal to
intermediate cell layers but undetectable in umbrella cells, the
terminally differentiated urothelial cells. This expression pattern
closely resembles that observed in the epidermis; p63 expression is
highest in keratinocyte stem cells (Pellegrini et al, 2001) and
gradually decreases along the differentiation axis (Parsa et al, 1999;
Bamberger et al, 2002). The p63 knockout mice show severe skin
defects (Mills et al, 1999; Yang et al, 1999), and remnant cells on
the defected skin express terminal differentiation markers (Yang
et al, 1999; Yang and McKeon, 2000), indicating physiological roles
of p63 in sustaining the stem cell population and regulating
differentiation of the epidermis. The urothelium also suffers from
severe defects in the p63
 /  mice (Yang et al, 1999). Taken
together, it appears likely that p63 plays critical roles in
maintaining normal urothelial structure and regulating differen-
tiation of the normal urothelium.
LPN tumours and normal urothelial cells of the basal cell
compartment showed essentially the same p63 expression profiles.
These data suggest that LPN tumours share common biological
characters with normal urothelium. Considering the possible roles
of p63 in the normal urothelium, LPN tumours might also require
p63 expression to maintain their structure. Interestingly, the
gradual diminution of p63 expression towards the superficial cell
layers (Figure 1C) implies that the normal epithelial differentiation
axis is still preserved in LPN tumours. Since LPN tumours actually
remain confined to the epithelial layers and have little propensity
for invasion and metastasis (Lee and Droller, 2000), it is
controversial to classify this phenotypic variant as true carcinoma
(Epstein et al, 1998). Our data may further support that LPN
tumours are close to normal epithelium and have little potential of
malignant progression.
High-grade invasive carcinomas, in clear contrast to LPN
tumours, showed frequent decrease or loss of p63 expression.
The mechanisms underlying impaired expression of p63 remain to
be elucidated. Reportedly, mutations of the p63 gene are rare in
human primary tumours including urothelial tumours (Osada et al,
1998; Hagiwara et al, 1999; Sunahara et al, 1999; Park et al, 2000).
In addition, we demonstrated that p53 status did not affect p63
expression in urothelial carcinomas, as previously reported (Park
et al, 2000). Taken together, impaired DNp63 expression in
urothelial carcinomas appears to be ascribed to epigenetic
modification independent of the p53 pathway.
b-Catenin plays a dual role in cell–cell adherent junctions (AJs)
and signal transduction that promotes cell proliferation (Conacci-
Sorrell et al, 2002). Cancer invasion and metastasis could be
promoted by not only disruption of AJs because of loss of E-
cadherin or a-catenin or tyrosine phosphorylation of AJ compo-
nents but also nuclear accumulation of b-catenin and consequent
transactivation of its target genes (Conacci-Sorrell et al, 2002).
Reduced expression of b-catenin that reflects defective AJs, on the
other hand, has been demonstrated to associate with progression
of urothelial carcinoma (Shimazui et al, 1996; Garcia del Muro et al,
2000). The latter process is rarely involved in urothelial neoplasms
as demonstrated in the current study and by others (Stoehr et al,
2002; Zhu et al, 2000). Interestingly, diminished DNp63 was
significantly associated with reduced b-catenin expression in the
present study. Recently, Patturajan et al. have reported that
downregulation of DNp63 decreases b-catenin levels in vitro in
squamous cell carcinoma cells (Patturajan et al, 2002). Taken
together, the impaired DNp63 expression might reduce b-catenin
expression, which possibly associates with aggressive biological
behaviour as well as malignant pathologic phenotypes of urothelial
neoplasms. In fact, reduced b-catenin associates with a worse
prognosis of bladder cancer patients (Shimazui et al, 1996; Garcia
del Muro et al, 2000).
In conclusion, our data clearly demonstrate that the normal p63
expression pattern is highly preserved in LPN tumours, whereas
frequently impaired in high-grade or invasive urothelial carcino-
mas. Moreover, impaired DNp63 expression associates with
reduced b-catenin. These data suggest that the impaired DNp63
expression characterises biological aggressiveness of urothelial
neoplasms.
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